These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21625848)

  • 1. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.
    Wilczynski J; Duechler M; Czyz M
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):289-99. PubMed ID: 21625848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
    Wilczynski J; Duechler M; Czyz M
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):301-7. PubMed ID: 21625847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
    Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF-κB and the link between inflammation and cancer.
    DiDonato JA; Mercurio F; Karin M
    Immunol Rev; 2012 Mar; 246(1):379-400. PubMed ID: 22435567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
    Lun M; Zhang PL; Siegelmann-Danieli N; Blasick TM; Brown RE
    Ann Clin Lab Sci; 2005; 35(1):15-24. PubMed ID: 15830705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
    Olivier S; Robe P; Bours V
    Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison.
    Görlach A; Bonello S
    Biochem J; 2008 Jun; 412(3):e17-9. PubMed ID: 18498249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer.
    Prasad S; Phromnoi K; Yadav VR; Chaturvedi MM; Aggarwal BB
    Planta Med; 2010 Aug; 76(11):1044-63. PubMed ID: 20635307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
    Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer research. Taking garbage in, tossing cancer out?
    Garber K
    Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.
    Sun HL; Liu YN; Huang YT; Pan SL; Huang DY; Guh JH; Lee FY; Kuo SC; Teng CM
    Oncogene; 2007 Jun; 26(27):3941-51. PubMed ID: 17213816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappaB in development, prevention, and therapy of cancer.
    Van Waes C
    Clin Cancer Res; 2007 Feb; 13(4):1076-82. PubMed ID: 17317814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis.
    Roman-Blas JA; Jimenez SA
    Int Rev Immunol; 2008; 27(5):351-74. PubMed ID: 18853343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor-kappaB activation: from bench to bedside.
    Sethi G; Sung B; Aggarwal BB
    Exp Biol Med (Maywood); 2008 Jan; 233(1):21-31. PubMed ID: 18156302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response.
    Rasmussen MK; Iversen L; Johansen C; Finnemann J; Olsen LS; Kragballe K; Gesser B
    Inflamm Res; 2008 Jul; 57(7):329-39. PubMed ID: 18607537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.